Orexo AB (publ) (0H19.IL)

18.14 +1.16 (+6.83%) At close: 07:05PM BST

Orexo AB (publ)

Rapsgatan 7E
Uppsala
Sweden
46 1 87 80 88 00
https://www.orexo.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 120

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Nikolaj Sorensen	Pres & CEO	5.78M	N/A	1972
Mr. Fredrik Jarrsten	Exec. VP & CFO	N/A	N/A	1967
Ms. Cecilia Coupland	Sr. VP & Head of Operations	N/A	N/A	1976
Lena Wange	Investor Relations & Communications Director	N/A	N/A	N/A
Mr. Robert Ronn	Sr. VP and Head of R&D	N/A	N/A	1976
Dr. Edward Kim M.B.A., M.D.	Chief Medical Officer	N/A	N/A	N/A
Mr. Robert A. Deluca	Pres of Orexo US Inc	N/A	N/A	1961
Mr. Jesper Lind	Advisor	N/A	N/A	1960

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is also developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Corporate governance

Orexo AB (publ)’s ISS governance QualityScore as of 1 October 2023 is 5. The pillar scores are Audit: 9; Board: 1; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.